Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis

American Journal of Gastroenterology

Volumn 91, Issue 11, 1996, Pages 2314-2317

  Batts, Kenneth P ^a,b   Jorgensen, Roberta A ^a   Dickson, E Rolland ^a   Lindor, Keith D ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEPATITIS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BILIRUBIN; BIOPSY; CHOLAGOGUES AND CHOLERETICS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 0029804380     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Leuschner U, Kurtz W. Pharmacological aspects and therapeutic effects of ursodeoxycholic acid. Dig Dis 1990;8:12-22.
2. Heller FR, Martinet JP, Henrion J, et al. The rationale for using ursodeoxycholic acid in chronic liver disease. Acta Gastroenterol Belg 1990;53:402-8.
3. Yoon YB, Hagey LR, Hofmann AF, et al. Effect of side chain shortening on the physiologic properties of bile acids: Hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 1986;90:837-52.
4. Hoffman AF, Popper H. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 1987;2:398.
5. Heuman DM, Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 1994;106:134-42.
6. 2+ signals in isolated rat hepatocytes. Gastroenterology 1993;104:604-12.
7. Guldutuna S, Zimmer G, Imhof M, et al. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993;104: 1736-44.
8. Facaille F, Paradis K. The immunosuppressive effect of ursodeoxycholic acid: A comparative in vitro study of human peripheral blood mononuclear cells. Hepatology 1993;18:165-72.
9. Yoshikawa M, Tsujii T, Matsumura K, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992;16:358-64.
10. Kurktschiev D, Subat S, Adler D, et al. Immunomodulating effect of ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. J Hepatol 1993;18:373-7.
11. Poupon RE, Balkau B, Eschwege E, et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324:1548-54.
12. Hwang SJ, Chan CY, Lee SD, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: A short-term, randomized, double-blind controlled cross-over study with long-term follow-up. J Gastroenterol Hepatol 1993;8:217-23.
13. Vuoristo M, Farkkila M, Karvonen A-L, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 1995;108:1470-8.
14. Hadziyannis SJ, Hadziyannis ES, Makris A. A randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1989;10:580 (abstract).
15. Matsuzaki Y, Tanaka N, Osuga T, et al. Improvement of biliary enzyme levels and itching as a result of long term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol 1990;85:15-23.
16. Battezzati PM, Podda M, Bianchi FB, et al. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis: Preliminary analysis of a double-blind multicenter trial. J Hepatol 1993;17:332-8.
17. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of Ursodeoxycholic Acid in Primary Biliary Cirrhosis. Hepatology 1994;19:1149-56.
18. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106: 1284-90.
19. Poupon RE, Poupon R, Balkau B, et al. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1342-7.
20. Heathcote EJ, Lindor KD, Poupon R, et al. Combined analysis of French, American, and Canadian randomized controlled trials of ursodeoxycholic acid therapy in primary biliary cirrhosis. Gastroenterology 1995;108:A1082 (abstract).
21. Batts KP, Jorgensen RA, Dickson ER, et al. The effects of ursodeoxycholic acid on hepatic inflammation and histologic stage in patients with primary biliary cirrhosis. Hepatology 1993;18:175 (abstract).
22. Ludwig J, Dickson ER, MacDonald GSA. Staging for nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A 1978;379:103-12.
23. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: Model for decision making. Hepatology 1989;10:1-7.
24. Leuschner U, Guldutunna S, Imhof M, et al. Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatology 1994;21:624-33.